Claims for Patent: 10,689,373

Summary for Patent: 10,689,373

Title:	1,2-substituted cyclopentanes as orexin receptor antagonists
Abstract:	The present invention provides compounds of formula (I) and pharmaceutically acceptable salts thereof, ##STR00001## wherein L, X, R.sup.a, R.sup.b, R.sup.1, R.sup.2 and R.sup.3 are as defined in the specification, processes for their preparation, pharmaceutical compositions containing them and their use in therapy.
Inventor(s):	Fieldhouse; Charlotte (Cambridgeshire, GB), Glen; Angela (Cambridgeshire, GB), Maine; Stephanie (Cambridgeshire, GB), Fujimoto; Tatsuhiko (Kanagawa, JP), Robinson; John Stephen (Cambridgeshire, GB)
Assignee:	TAKEDA PHARMACEUTICAL COMPANY LIMITED (Osaka, JP)
Application Number:	15/995,586
Patent Claims:	1. A method of treating a disease, disorder, or condition linked to orexin receptor activity in a subject, wherein the disease, disorder, or condition linked to orexin receptor activity is selected from the group consisting of: schizophrenia, psychotic disorder, psychosis, schizoaffective disorder, dementia, generalized anxiety disorder, post-traumatic stress disorder, panic disorders, acute stress disorder, social anxiety disorder, phobias including agoraphobia, obsessive compulsive disorder, trichotillomania, body dismorphic disorder, bipolar I, bipolar II, bipolar mania, bipolar depression, substance dependence, alcohol dependence, nicotine dependence, gambling disorder, binge eating, bulimia nervosa, anorexia nervosa, obesity, rapid eye movement sleep disorder, attention-deficit disorder, autistic spectrum disorders, Rett syndrome, Fragile X syndrome, Asperger syndrome, disruptive behaviour disorders, restless leg syndrome, pain, Parkinson's disease, and Alzheimer's disease, and wherein the method comprises administering to the subject a therapeutically effective amount of a compound of formula (I): ##STR00241## wherein R.sup.1 represents a 5- or 6-membered heteroaryl group optionally substituted by at least one substituent selected from halogen, cyano, hydroxyl, C.sub.3-C.sub.6 cycloalkyl, C.sub.1-C.sub.3 alkyl, C.sub.1-C.sub.3 alkoxy, C.sub.1-C.sub.3 alkoxycarbonyl, C.sub.1-C.sub.3 alkoxycarbonylamino, C.sub.1-C.sub.3 haloalkyl, C.sub.1-C.sub.3 haloalkoxy, --NR.sup.4R.sup.5, C.sub.3-C.sub.6 cycloalkylamino, C.sub.1-C.sub.3 alkylcarbonyloxy, C.sub.1-C.sub.3 alkylcarbonylamino, sulphonamido, C.sub.1-C.sub.3 alkylsulphonyl, C.sub.1-C.sub.3 alkylsulphonylamino and --C(O)NR.sup.6R.sup.7; L represents a bond, CH.sub.2, O or NR.sup.12; R.sup.a represents a hydrogen atom or a C.sub.1-C.sub.3 alkyl or C.sub.1-C.sub.3 haloalkyl group; R.sup.b represents a hydrogen atom or a C.sub.1-C.sub.3 alkyl or C.sub.1-C.sub.3 haloalkyl group; X represents CH.sub.2, CHF or CF.sub.2; R.sup.2 represents a hydrogen atom or a C.sub.1-C.sub.6 alkyl or C.sub.3-C.sub.6 cycloalkyl group; R.sup.3 represents a phenyl group or a 5- or 6-membered heteroaryl group, all optionally substituted by at least one substituent independently selected from halogen, hydroxyl, cyano, C.sub.1-C.sub.3 alkyl, C.sub.1-C.sub.3 haloalkyl, C.sub.1-C.sub.3 hydroxyalkyl, C.sub.1-C.sub.3 alkoxy, C.sub.1-C.sub.3 haloalkoxy, C.sub.2-C.sub.4 alkenyl, C.sub.1-C.sub.3 alkylcarbonyloxy, C.sub.1-C.sub.3 alkoxycarbonyl, --NR.sup.8R.sup.9, --C(O)NR.sup.10R.sup.11, C.sub.3-C.sub.6 cycloalkyl, C.sub.3-C.sub.6 cycloalkyloxy, C.sub.3-C.sub.6 cycloalkylmethyl or a 5- or 6-membered heteroaryl group, the heteroaryl group itself being optionally substituted by at least one substituent independently selected from C.sub.1-C.sub.6 alkyl, C.sub.1-C.sub.6 alkoxy and C.sub.1-C.sub.6 haloalkoxy; R.sup.4 and R.sup.5 each independently represent a hydrogen atom or a C.sub.1-C.sub.3 alkyl or C.sub.3-C.sub.6 cycloalkyl group, or R.sup.4 and R.sup.5 may together with the nitrogen atom to which they are attached form a 4- to 7-membered saturated heterocyclic ring optionally substituted by at least one substituent independently selected from halogen, hydroxyl and C.sub.1-C.sub.3 alkoxy; R.sup.6 and R.sup.7 each independently represent a hydrogen atom or a C.sub.1-C.sub.3 alkyl or C.sub.3-C.sub.6 cycloalkyl group, or R.sup.6 and R.sup.7 may together with the nitrogen atom to which they are attached form a 4- to 7-membered saturated heterocyclic ring optionally substituted by at least one substituent independently selected from halogen and hydroxyl; R.sup.8 and R.sup.9 each independently represent a hydrogen atom or a C.sub.1-C.sub.3 alkyl or C.sub.3-C.sub.6 cycloalkyl group, or R.sup.8 and R.sup.9 may together with the nitrogen atom to which they are attached form a 4- to 7-membered saturated heterocyclic ring optionally substituted by at least one substituent independently selected from halogen, hydroxyl and C.sub.1-C.sub.3 alkoxy; R.sup.10 and R.sup.11 each independently represent a hydrogen atom or a C.sub.1-C.sub.3 alkyl or C.sub.3-C.sub.6 cycloalkyl group, or R.sup.10 and R.sup.11 may together with the nitrogen atom to which they are attached form a 4- to 7-membered saturated heterocyclic ring optionally substituted by at least one substituent independently selected from halogen and hydroxyl; and R.sup.12 represents a hydrogen atom, methyl group or a C.sub.2-C.sub.3 alkylene chain that links to R.sup.1 to form a 5- or 6-membered ring; or enantiomers thereof or a pharmaceutically acceptable salt thereof. 2. The method according to claim 1, wherein R.sup.1 represents a 5- or 6-membered heteroaryl group containing one or two ring heteroatoms independently selected from nitrogen, oxygen and sulphur, the heteroaryl group being optionally substituted by one or two substituents independently selected from halogen, C.sub.1-C.sub.3 alkyl and C.sub.1-C.sub.3 haloalkyl. 3. The method according to claim 1, wherein R.sup.1 represents a 5- or 6-membered heteroaryl group selected from pyridinyl, pyrimidinyl and pyrazinyl, all optionally substituted as defined in claim 1. 4. The method according to claim 3, wherein R.sup.1 represents a group selected from: (i) 4-(trifluoromethyl)pyridin-2-yl, (ii) 5-(trifluoromethyl)pyridin-2-yl, (iii) 5-(trifluoromethoxy)pyridin-2-yl, (iv) 6-(trifluoromethyl)pyridin-2-yl, (v) 6-(trifluoromethyl)pyridin-3-yl, (vi) 5-chloropyridin-2-yl, (vii) 5-bromopyridin-2-yl, (viii) 3-fluoro-5-(trifluoromethyl)pyridin-2-yl, (ix) 3-chloro-5-(trifluoromethyl)pyridin-2-yl, (x) 3-bromo-5-(trifluoromethyl)pyridin-2-yl, (xi) 5-bromo-3-methoxypyridin-2-yl, (xii) 3-methyl-5-(trifluoromethyl)pyridin-2-yl, (xiii) 5-(trifluoromethyl)pyrimidin-2-yl, (xiv) 5-ethylpyrimidin-2-yl, (xv) 5-(trifluoromethyl)pyrazin-2-yl, (xvi) 5-chloropyrazin-2-yl, (xvii) 5-(ethyl)pyrazin-2-yl, (xviii) 5-(cyclopropyl)pyrazin-2-yl, (xix) 5-(isopropyl)pyrazin-2-yl, (xx) 3-methyl-5-(trifluoromethyl)pyrazin-2-yl, (xxi) 3-ethyl-5-(trifluoromethyl)pyrazin-2-yl, (xxii) 3-cyclopropyl-5-(trifluoromethyl)pyrazin-2-yl, and (xxiii) 3-isopropyl-5-(trifluoromethyl)pyrazin-2-yl. 5. The method according to claim 1, wherein X represents CH.sub.2. 6. The method according to claim 1, wherein L represents NH. 7. The method according to claim 1, wherein R.sup.2 represents a hydrogen atom. 8. The method according to claim 1, wherein R.sup.3 represents a 5- or 6-membered heteroaryl group selected from pyridinyl, pyrimidinyl and pyrazinyl, all optionally substituted as defined in claim 1. 9. The method according to claim 1, wherein R.sup.3 represents a phenyl group optionally substituted by at least one substituent independently selected from fluorine, chlorine, C.sub.1-C.sub.3 alkyl, C.sub.1-C.sub.3 alkoxy or a 5- or 6-membered heteroaryl group, the heteroaryl group itself being optionally substituted by one or two substituents independently selected from C.sub.1-C.sub.2 alkyl, C.sub.1-C.sub.2 alkoxy and C.sub.1-C.sub.2 haloalkoxy. 10. The method according to claim 1, wherein R.sup.3 represents a group selected from: (i) 2-fluorophenyl, (ii) 2-chlorophenyl, (iii) 2-methylphenyl, (iv) 2-cyclopropylphenyl, (v) 2-methoxyphenyl, (vi) 2-ethoxyphenyl, (vii) 2-(difluoromethoxy)phenyl, (viii) 3-methylphenyl, (ix) 3-methoxyphenyl, (x) 2,6-difluorophenyl, (xi) 2,6-dichlorophenyl, (xii) 2,6-dimethoxyphenyl, (xiii) 2,6-diethoxyphenyl, (xiv) 2-ethoxy-5-methylphenyl, (xv) 2,5-dimethoxyphenyl, (xvi) 2-fluoro-6-methoxyphenyl, (xvii) 5-fluoro-2-methoxyphenyl, (xviii) 3-fluoro-2-methoxyphenyl, (xix) 2-(1H-1,2,4-triazol-1-yl)phenyl, (xx) 2-(2H-1,2,3-triazol-2-yl)phenyl, (xxi) 5-methyl-2-(1H-1,2,3-triazol-1-yl)phenyl, (xxii) 5-methyl-2-(2H-1,2,3-triazol-2-yl)phenyl, (xxiii) 5-fluoro-2-(1H-1,2,3-triazol-1-yl)phenyl, (xxiv) 5-fluoro-2-(2H-1,2,3-triazol-2-yl)phenyl, (xxv) 2-(3-methyl-1,2,4-oxadiazol-5-yl)phenyl, (xxvi) 2-(pyrimidin-2-yl)phenyl, (xxvii) 5-fluoro-2-(pyrimidin-2-yl)phenyl, (xxviii) 2-(1H-pyrazol-1-yl)phenyl, (xxix) 2-(1H-imidazol-1-yl)phenyl, (xxx) 2-(1H-1,2,3-triazol-1-yl)phenyl, (xxxi) 2-(pyrimidin-2-yl)-5-fluorophenyl, (xxxii) 2-fluoro-6-(2H-1,2,3-triazol-2-yl)phenyl, (xxxiii) 2-methoxy-5-methylphenyl, (xxxiv) 2-chloro-6-(2H-1,2,3-triazol-2-yl)phenyl, (xxxv) 2-(5-methyl-1,3,4-oxadiazol-2-yl)phenyl, (xxxvi) 5-trifluoromethyl-2-(2H-1,2,3-triazol-2-yl)phenyl, (xxxvii) 2-fluoro-6-(pyrazol-1-yl)phenyl, (xxxviii) 5-fluoro-2-(pyrazol-1-yl)phenyl, (xxxix) 5-methyl-2-(pyrazol-1-yl)phenyl, (xl) 2-bromo-6-methoxyphenyl, (xli) 2-methoxy-6-(pyrazol-1-yl)phenyl, (xlii) 5-chloro-2-(2H-1,2,3-triazol-2-yl)phenyl, (xliii) 3-fluoro-2-(2H-1,2,3-triazol-2-yl)phenyl, (xliv) 5-trifluoromethyl-2-(1H-1,2,3-triazol-1-yl)phenyl, (xlv) 5-chloro-2-(1H-1,2,3-triazol-1-yl)phenyl, (xlvi) 2,3-difluoro-6-(2H-1,2,3-triazol-2-yl)phenyl, (xlvii) 5-cyclopropyl-2-(2H-1,2,3-triazol-2-yl)phenyl, (xlviii) 5-chloro-2-(pyrazol-1-yl)phenyl, (xlix) 3,5-difluoro-2-(2H-1,2,3-triazol-2-yl)phenyl, (l) 2-(difluoromethyl)phenyl, (li) 2-(trifluoromethyl)phenyl, (lii) 3,6-difluoro-2-(2H-1,2,3-triazol-2-yl)phenyl, (liii) 2-cyclopropyl-6-fluorophenyl, (liv) 2-(5-ethoxypyrimidin-2-yl)phenyl, (lv) 3-(pyrimidin-2-yl)pyridin-2-yl, (lvi) 3-ethoxy-6-methylpyridin-2-yl, (lvii) 3-(pyrazol-1-yl)pyridin-2-yl, (lviii) 3-(piperidin-1-yl)pyridin-2-yl, (lix) 3-(trifluoromethoxy)pyridin-2-yl, (lx) 3-(ethoxy)pyridin-2-yl, (lxi) 3-(cyclopropyl)pyridin-2-yl, (lxii) 3-chloropyridin-2-yl, (lxiii) 3-bromopyridin-2-yl, (lxiv) 3-methoxypyridin-2-yl, (lxv) 3-(propan-2-yloxy)pyridin-2-yl, (lxvi) 6-bromo-3-methoxypyridin-2-yl, (lxvii) 3-methoxy-6-methylpyridin-2-yl, and (lxviii) 3-(2H-1,2,3-triazol-2-yl)pyridin-2-yl. 11. The method according to claim 1, wherein the compound of formula (I) is selected from the group consisting of: 2,6-Dimethoxy-N-[(1S,2S)-2-{[5-(trifluoromethyl)pyridin-2-yl]amino}cyclop- entyl]benzamide; 2,6-Dimethoxy-N-[(1S,2S)-2-{[5-(trifluoromethyl)pyrimidin-2-yl]amino}cycl- opentyl]benzamide; 5-Methyl-2-(2H-1,2,3-triazol-2-yl)-N-[(1S,2S)-2-{[5-(trifluoromethyl)pyri- midin-2-yl]amino}cyclopentyl]benzamide; N-[(1S,2S)-2-[(5-Ethylpyrimidin-2-yl)amino]cyclopentyl]-5-methyl-2-(2H-1,- 2,3-triazol-2-yl)benzamide; N-[(1S,2S)-2-[(5-Chloropyridin-2-yl)amino]cyclopentyl]-5-methyl-2-(2H-1,2- ,3-triazol-2-yl)benzamide; 5-Methyl-2-(2H-1,2,3-triazol-2-yl)-N-[(1S,2S)-2-{[5-(trifluoromethyl)pyri- din-2-yl]amino}cyclopentyl]benzamide; 5-Methyl-2-(2H-1,2,3-triazol-2-yl)-N-[(1S,2S)-2-{[5-(trifluoromethyl)pyra- zin-2-yl]amino}cyclopentyl]benzamide; 2-(3-Methyl-1,2,4-oxadiazol-5-yl)-N-[(1S,2S)-2-{[5-(trifluoromethyl)pyrid- in-2-yl]amino}cyclopentyl]benzamide; N-[(1S,2S)-2-[(5-Chloropyrazin-2-yl)amino]cyclopentyl]-5-methyl-2-(2H-1,2- ,3-triazol-2-yl)benzamide; 5-Fluoro-2-(2H-1,2,3-triazol-2-yl)-N-[(1S,2S)-2-{[5-(trifluoromethyl)pyri- din-2-yl]amino}cyclopentyl]benzamide; 2-(1H-Pyrazol-1-yl)-N-[(11S,2S)-2-{[5-(trifluoromethyl)pyridin-2-yl]amino- }cyclopentyl]benzamide; 2-(2H-1,2,3-Triazol-2-yl)-N-[(1S,2S)-2-{[5-(trifluoromethyl)pyridin-2-yl]- amino}cyclopentyl]benzamide; 2-(Pyrimidin-2-yl)-N-[(1S,2S)-2-{[5-(trifluoromethyl)pyridin-2-yl]amino}c- yclopentyl]benzamide; 5-Fluoro-2-(pyrimidin-2-yl)-N-[(1S,2S)-2-{[5-(trifluoromethyl)pyridin-2-y- l]amino}cyclopentyl]benzamide; 2-(3-Methyl-1,2,4-oxadiazol-5-yl)-N-[(1S,2S)-2-{[5-(trifluoromethyl)pyraz- in-2-yl]amino}cyclopentyl]benzamide; 2-(3-Methyl-1,2,4-oxadiazol-5-yl)-N-[(1S,2S)-2-{[5-(trifluoromethyl)pyrim- idin-2-yl]amino}cyclopentyl]benzamide; 2-(2H-1,2,3-Triazol-2-yl)-N-[(1S,2S)-2-{[5-(trifluoromethyl)pyrazin-2-yl]- amino}cyclopentyl]benzamide; 2-(2H-1,2,3-Triazol-2-yl)-N-[(1S,2S)-2-{[5-(trifluoromethyl)pyrimidin-2-y- l]amino}cyclopentyl]benzamide; 2-(2H-1,2,3-Triazol-2-yl)-N-[(1S,2R)-2-{[5-(trifluoromethyl)pyrazin-2-yl]- oxy}cyclopentyl]benzamide; 2-(2H-1,2,3-Triazol-2-yl)-N-[(1S,2S)-2-{[4-(trifluoromethyl)pyridin-2-yl]- oxy}cyclopentyl]benzamide; 2,6-Dimethoxy-N-[(1S,2S)-2-{[4-(trifluoromethyl)pyridin-2-yl]oxy}cyclopen- tyl]benzamide; 2-(2H-1,2,3-Triazol-2-yl)-N-(2-{[4-(trifluoromethyl)pyridin-2-yl]methyl}c- yclopentyl)benzamide; 2-(2H-1,2,3-Triazol-2-yl)-N-(2-{[5-(trifluoromethyl)pyridin-2-yl]methyl}c- yclopentyl)benzamide; 5-Methyl-2-(2H-1,2,3-triazol-2-yl)-N-(2-{[5-(trifluoromethyl)pyridin-2-yl- ]methyl}cyclopentyl)benzamide; 2,6-Dimethoxy-N-[(1S,2S)-2-{[6-(trifluoromethyl)pyridin-2-yl]amino}cyclop- entyl]benzamide; 3-Bromo-N-[(1S,2S)-2-{[5-(trifluoromethyl)pyrazin-2-yl]amino}cyclopentyl]- pyridine-2-carboxamide; 2-Ethoxy-5-methyl-N-[(1S,2S)-2-{[5-(trifluoromethyl)pyrazin-2-yl]amino}cy- clopentyl]benzamide; 3-Ethoxy-6-methyl-N-[(1S,2S)-2-{[5-(trifluoromethyl)pyrazin-2-yl]amino}cy- clopentyl]pyridine-2-carboxamide; 2-(1H-Pyrazol-1-yl)-N-[(1S,2S)-2-{[5-(trifluoromethyl)pyrazin-2-yl]amino}- cyclopentyl]benzamide; 2-Fluoro-6-(2H-1,2,3-triazol-2-yl)-N-[(1S,2S)-2-{[5-(trifluoromethyl)pyra- zin-2-yl]amino}cyclopentyl]benzamide; 2,6-Difluoro-N-[(1S,2S)-2-{[5-(trifluoromethyl)pyrazin-2-yl]amino}cyclope- ntyl]benzamide; 2,6-Dimethoxy-N-[(1S,2S)-2-{[5-(trifluoromethyl)pyrazin-2-yl]amino}cyclop- entyl]benzamide; 2-(1H-1,2,3-Triazol-1-yl)-N-[(1S,2S)-2-{[5-(trifluoromethyl)pyrazin-2-yl]- amino}cyclopentyl]benzamide; 5-Fluoro-2-(2H-1,2,3-triazol-2-yl)-N-[(1S,2S)-2-{[5-(trifluoromethyl)pyra- zin-2-yl]amino}cyclopentyl]benzamide; 2-Methoxy-5-methyl-N-[(1S,2S)-2-{[5-(trifluoromethyl)pyrazin-2-yl]amino}c- yclopentyl]benzamide; 2-(Pyrimidin-2-yl)-N-[(1S,2S)-2-{[5-(trifluoromethyl)pyrazin-2-yl]amino}c- yclopentyl]benzamide; 5-Fluoro-2-(pyrimidin-2-yl)-N-[(1S,2S)-2-{[5-(trifluoromethyl)pyrazin-2-y- l]amino}cyclopentyl]benzamide; 2-Chloro-6-(2H-1,2,3-triazol-2-yl)-N-[(1S,2S)-2-{[5-(trifluoromethyl)pyra- zin-2-yl]amino}cyclopentyl]benzamide; 5-Fluoro-2-(1H-1,2,3-triazol-1-yl)-N-[(1S,2S)-2-{[5-(trifluoromethyl)pyra- zin-2-yl]amino}cyclopentyl]benzamide; 5-Methyl-2-(1H-1,2,3-triazol-1-yl)-N-[(1S,2S)-2-{[5-(trifluoromethyl)pyra- zin-2-yl]amino}cyclopentyl]benzamide; 3-(1H-Pyrazol-1-yl)-N-[(11S,2S)-2-{[5-(trifluoromethyl)pyrazin-2-yl]amino- }cyclopentyl]pyridine-2-carboxamide; 2-(5-Methyl-1,3,4-oxadiazol-2-yl)-N-[(1S,2S)-2-{[5-(trifluoromethyl)pyraz- in-2-yl]amino}cyclopentyl]benzamide; 2-(2H-1,2,3-Triazol-2-yl)-5-(trifluoromethyl)-N-[(11S,2S)-2-{[5-(trifluor- omethyl)pyrazin-2-yl]amino}cyclopentyl]benzamide; 2-Fluoro-6-(1H-pyrazol-1-yl)-N-[(1S,2S)-2-{[5-(trifluoromethyl)pyrazin-2-- yl]amino}cyclopentyl]benzamide; 5-Fluoro-2-(1H-pyrazol-1-yl)-N-[(1S,2S)-2-{[5-(trifluoromethyl)pyrazin-2-- yl]amino}cyclopentyl]benzamide; 5-Methyl-2-(1H-pyrazol-1-yl)-N-[(1S,2S)-2-{[5-(trifluoromethyl)pyrazin-2-- yl]amino}cyclopentyl]benzamide; 2-Bromo-6-methoxy-N-[(1S,2S)-2-{[5-(trifluoromethyl)pyrazin-2-yl]amino}cy- clopentyl]benzamide; 2-Methoxy-6-(1H-pyrazol-1-yl)-N-[(1S,2S)-2-{[5-(trifluoromethyl)pyrazin-2- -yl]amino}cyclopentyl]benzamide; 3-Piperidin-1-yl)-N-[(1S,2S)-2-{[5-(trifluoromethyl)pyrazin-2-yl]amino}cy- clopentyl]pyridine-2-carboxamide, 5-Chloro-2-(2H-1,2,3-triazol-2-yl)-N-[(1S,2S)-2-{[5-trifluoromethyl)pyraz- in-2-yl]amino}cyclopentyl]benzamide; 3-Fluoro-2-(2H-1,2,3-triazol-2-yl)-N-[(1S,2S)-2-{[5-(trifluoromethyl)pyra- zin-2-yl]amino}cyclopentyl]benzamide; 2-(1H-1,2,3-Triazol-1-yl)-5-(trifluoromethyl)-N-[(1S,2S)-2-{[5-(trifluoro- methyl)pyrazin-2-yl]amino}cyclopentyl]benzamide; 5-Chloro-2-(1H-1,2,3-triazol-1-yl)-N-[(1S,2S)-2-{[5-(trifluoromethyl)pyra- zin-2-yl]amino}cyclopentyl]benzamide; 2,3-Difluoro-6-(2H-1,2,3-triazol-2-yl)-N-[(1S,2S)-2-{[5-(trifluoromethyl)- pyrazin-2-yl]amino}cyclopentyl]benzamide; 5-Cyclopropyl-2-(2H-1,2,3-triazol-2-yl)-N-[(1S,2S)-2-{[5-(trifluoromethyl- )pyrazin-2-yl]amino}cyclopentyl]benzamide; 3-(Trifluoromethoxy)-N-[(1S,2S)-2-{[5-(trifluoromethyl)pyrazin-2-yl]amino- }cyclopentyl]pyridine-2-carboxamide; 5-Chloro-2-(1H-pyrazol-1-yl)-N-[(1S,2S)-2-{[5-(trifluoromethyl)pyrazin-2-- yl]amino}cyclopentyl]benzamide; 3-Ethoxy-N-[(1S,2S)-2-{[5-(trifluoromethyl)pyrazin-2-yl]amino}cyclopentyl- ]pyridine-2-carboxamide; 3,5-Difluoro-2-(2H-1,2,3-triazol-2-yl)-N-[(1S,2S)-2-{[5-(trifluoromethyl)- pyrazin-2-yl]amino}cyclopentyl]benzamide; 2-(Trifluoromethyl)-N-[(1S,2)-2-{[5-(trifluoromethyl)pyrazin-2-yl]amino}c- yclopentyl]benzamide; 3-Cyclopropyl-N-[(1S,2S)-2-{[5-(trifluoromethyl)pyrazin-2-yl]amino}cyclop- entyl]pyridine-2-carboxamide; 3,6-Difluoro-2-(2H-1,2,3-triazol-2-yl)-N-[(1S,2S)-2-{[5-(trifluoromethyl)- pyrazin-2-yl]amino}cyclopentyl]benzamide; 2-(Difluoromethyl)-N-[(1S,2S)-2-{[5-(trifluoromethyl)pyrazin-2-yl]amino}c- yclopentyl]benzamide; 2-Cyclopropyl-6-fluoro-N-[(1S,2S)-2-{[5-(trifluoromethyl)pyrazin-2-yl]ami- no}cyclopentyl]benzamide; 5-Methyl-2-(2H-1,2,3-triazol-2-yl)-N-[(1S,2S)-2-{[6-(trifluoromethyl)pyri- din-3-yl]amino}cyclopentyl]benzamide; N-Cyclobutyl-2,6-dimethoxy-N-[(1S,2S)-2-{[5-(trifluoromethyl)pyridin-2-yl- ]amino}cyclopentyl]benzamide; 2-Chloro-N-[(1S,2S)-2-{[5-(trifluoromethyl)pyridin-2-yl]amino}cyclopentyl- ]benzamide; 2-Chloro-N-[(1S,2S)-2-{[5-(trifluoromethyl)pyrimidin-2-yl]amino}cyclopent- yl]benzamide; 2-Fluoro-6-methoxy-N-[(1S,2S)-2-{[5-(trifluoromethyl)pyridin-2-yl]amino}c- yclopentyl]benzamide; 2,6-Difluoro-N-[(1S,2S)-2-{[5-(trifluoromethyl)pyridin-2-yl]amino}cyclope- ntyl]benzamide; N-[(1S,2S)-2-{Methyl[5-(trifluoromethyl)pyrazin-2-yl]amino}cyclopentyl]-2- -(2H-1,2,3-triazol-2-yl)benzamide; 5-Fluoro-N-[(1S,2S)-2-{methyl[5-(trifluoromethyl)pyrazin-2-yl]amino}cyclo- pentyl]-2-(2H-1,2,3-triazol-2-yl)benzamide; 2-Fluoro-N-[(1S,2S)-2-{methyl[5-(trifluoromethyl)pyrazin-2-yl]amino}cyclo- pentyl]-6-(2H-1,2,3-triazol-2-yl)benzamide; N-[(1S,2S)-2-{[3-Methyl-5-(trifluoromethyl)pyrazin-2-yl]amino}cyclopentyl- ]-3-(2H-1,2,3-triazol-2-yl)pyridine-2-carboxamide; N-[(1S,2S)-2-Methyl-2-{[5-(trifluoromethyl)pyrazin-2-yl]amino}cyclopentyl- ]-3-(2H-1,2,3-triazol-2-yl)pyridine-2-carboxamide; N-[(11S,2S)-2-{[3-Methyl-5-(trifluoromethyl)pyrazin-2-yl]amino}cyclopenty- l]-2-(2H-1,2,3-triazol-2-yl)benzamide; N-[(1S,2S)-2-{[3-Methyl-5-(trifluoromethyl)pyrazin-2-yl]amino}cyclopentyl- ]-2-(pyrimidin-2-yl)benzamide; 5-Fluoro-N-[(1S,2S)-2-{[3-methyl-5-(trifluoromethyl)pyrazin-2-yl]amino}cy- clopentyl]-2-(pyrimidin-2-yl)benzamide; N-[1S,2S)-2-Methyl-2-{[5-(trifluoromethyl)pyrazin-2-yl]amino}cyclopentyl]- -2-(2H-1,2,3-triazol-2-yl)benzamide; N-(2-Methyl-2-{[5-(trifluoromethyl)pyrazin-2-yl]amino}cyclopentyl)-2-(2H-- 1,2,3-triazol-2-yl)benzamide; N-[(1R,2R)-2-Methyl-2-{[5-(trifluoromethyl)pyrazin-2-yl]amino}cyclopentyl- ]-2-(2H-1,2,3-triazol-2-yl)benzamide; 5-Fluoro-N-[(1S,2S)-2-methyl-2-{[5-(trifluoromethyl)pyrazin-2-yl]amino}cy- clopentyl]-2-(2H-1,2,3-triazol-2-yl)benzamide; N-[(11S,2S)-2-Methyl-2-{[5-(trifluoromethyl)pyrazin-2-yl]amino}cyclopenty- l]-3-(1H-pyrazol-1-yl)pyridine-2-carboxamide; 3-Ethoxy-N-[(1S,2S)-2-methyl-2-{[5-(trifluoromethyl)pyrazin-2-yl]amino}cy- clopentyl]pyridine-2-carboxamide, 2-Chloro-N-[(1S,2S)-2-methyl-2-{[5-(trifluoromethyl)pyrazin-2-yl]amino}cy- clopentyl]-6-(2H-1,2,3-triazol-2-yl)benzamide; 2,6-Difluoro-N-[(1S,2S)-2-methyl-2-{[5-(trifluoromethyl)pyrazin-2-yl]amin- o}cyclopentyl]benzamide; 3-Cyclopropyl-N-[(1S,2S)-2-methyl-2-{[5-(trifluoromethyl)pyrazin-2-yl]ami- no}cyclopentyl]pyridine-2-carboxamide; N-[(1S,2S)-2-Methyl-2-{[5-(trifluoromethyl)pyrazin-2-yl]amino}cyclopentyl- ]-3-(trifluoromethoxy)pyridine-2-carboxamide; N-[(1S,2S)-2-Methyl-2-{[5-(trifluoromethyl)pyrazin-2-yl]amino}cyclopentyl- ]-2-(pyrimidin-2-yl)benzamide; 5-Chloro-N-[(1S,2S)-2-methyl-2-{[5-(trifluoromethyl)pyrazin-2-yl]amino}cy- clopentyl]-2-(2H-1,2,3-triazol-2-yl)benzamide; N-(2-Methyl-2-{[5-(trifluoromethyl)pyrimidin-2-yl]amino}cyclopentyl)-2-(2- H-1,2,3-triazol-2-yl)benzamide; N-(2-Methyl-2-{[5-(trifluoromethyl)pyridin-2-yl]amino}cyclopentyl)-2-(2H-- 1,2,3-triazol-2-yl)benzamide; N-(2-Methyl-2-{[5-(trifluoromethoxy)pyridin-2-yl]amino}cyclopentyl)-2-(2H- -1,2,3-triazol-2-yl)benzamide; 5-Chloro-2-(2H-1,2,3-triazol-2-yl)-N-[(1S,2S)-2-{[5-(trifluoromethyl)pyri- din-2-yl]amino}cyclopentyl]benzamide; 3-Fluoro-2-(2H-1,2,3-triazol-2-yl)-N-[(1S,2S)-2-{[5-(trifluoromethyl)pyri- din-2-yl]amino}cyclopentyl]benzamide; 3,5-Difluoro-2-(2H-1,2,3-triazol-2-yl)-N-[(1S,2S)-2-{[5-(trifluoromethyl)- pyridin-2-yl]amino}cyclopentyl]benzamide; 3-(2H-1,2,3-Triazol-2-yl)-N-[(1S,2S)-2-{[5-(trifluoromethyl)pyridin-2-yl]- amino}cyclopentyl]pyridine-2-carboxamide; 3-(1H-Pyrazol-1-yl)-N-[(1S,2S)-2-{[5-(trifluoromethyl)pyridin-2-yl]amino}- cyclopentyl]pyridine-2-carboxamide; 2-Fluoro-6-(2H-1,2,3-triazol-2-yl)-N-[(1S,2S)-2-{[5-(trifluoromethyl)pyri- din-2-yl]amino}cyclopentyl]benzamide; N-(2-{[3-Fluoro-5-(trifluoromethyl)pyridin-2-yl]amino}-2-methylcyclopenty- l)-3-(2H-1,2,3-triazol-2-yl)pyridine-2-carboxamide; N-[(1S,2S)-2-{[3-Fluoro-5-(trifluoromethyl)pyridin-2-yl]amino}cyclopentyl- ]-2-(2H-1,2,3-triazol-2-yl)benzamide; N-[(1S,2S)-2-{[3-Chloro-5-(trifluoromethyl)pyridin-2-yl]amino}cyclopentyl- ]-2-(2H-1,2,3-triazol-2-yl)benzamide; N-[(1S,2S)-2-{[3-Bromo-5-(trifluoromethyl)pyridin-2-yl]amino}cyclopentyl]- -2-(2H-1,2,3-triazol-2-yl)benzamide; N-[(1S,2S)-2-{[3-Methyl-5-(trifluoromethyl)pyridin-2-yl]amino}cyclopentyl- ]-2-(2H-1,2,3-triazol-2-yl)benzamide; N-[(1S,2S)-2-{[3-Cyclopropyl-5-(trifluoromethyl)pyrazin-2-yl]amino}cyclop- entyl]-2-(2H-1,2,3-triazol-2-yl)benzamide; N-[(1S,2S)-2-{[3-(Propan-2-yl)-5-(trifluoromethyl)pyrazin-2-yl]amino}cycl- opentyl]-2-(2H-1,2,3-triazol-2-yl)benzamide; N-[(1S,2S)-2-{[3-Ethyl-5-(trifluoromethyl)pyrazin-2-yl]amino}cyclopentyl]- -2-(2H-1,2,3-triazol-2-yl)benzamide; N-[(1S,2S)-2-[(5-Cyclopropylpyrazin-2-yl)amino]cyclopentyl]-2-(2H-1,2,3-t- riazol-2-yl)benzamide; N-[(1S,2S)-2-{[5-Propan-2-yl)pyrazin-2-yl]amino}cyclopentyl]-2-(2H-1,2,3-- triazol-2-yl)benzamide; N-[(1S,2S)-2-[(5-Ethylpyrazin-2-yl)amino]cyclopentyl]-2-(2H-1,2,3-triazol- -2-yl)benzamide; 2-(2H-1,2,3-Triazol-2-yl)-N-[(1S,2S)-2-{[5-(trifluoromethoxy)pyridin-2-yl- ]amino}cyclopentyl]benzamide; 5-Chloro-2-(2H-1,2,3-triazol-2-yl)-N-[(1S,2S)-2-{[5-(trifluoromethoxy)pyr- idin-2-yl]amino}cyclopentyl]benzamide; N-[(1S,2S)-2-[(5-Bromopyridin-2-yl)amino]cyclopentyl]-2-(2H-1,2,3-triazol- -2-yl)benzamide; N-[(1S,2S)-2-[(5-Bromo-3-methoxypyridin-2-yl)amino]cyclopentyl]-2-(2H-1,2- ,3-triazol-2-yl)benzamide; 2-(2H-1,2,3-Triazol-2-yl)-N-[(1S,2S)-2-{[4-(trifluoromethyl)pyridin-2-yl]- amino}cyclopentyl]benzamide; N-[(1S,2S)-2-{[3-Chloro-5-(trifluoromethyl)pyridin-2-yl]amino}cyclopentyl- ]-3-(2-1,2,3-triazol-2-yl)pyridine-2-carboxamide; N-[(1S,2S)-2-{[3-Fluoro-5-(trifluoromethyl)pyridin-2-yl]amino}cyclopentyl- ]-3-(2H-1,2,3-triazol-2-yl)pyridine-2-carboxamide; N-[(1S,2S)-2-{[3-Methyl-5-(trifluoromethyl)pyridin-2-yl]amino}cyclopentyl- ]-3-(2H-1,2,3-triazol-2-yl)pyridin-2-carboxamide; N-[(1S,2S)-2-{[3-Ethyl-5-(trifluoromethyl)pyrazin-2-yl]amino}cyclopentyl]- -3-(2H-1,2,3-triazol-2-yl)pyridine-2-carboxamide; N-(4,4-Difluoro-2-{[5-(trifluoromethyl)pyrazin-2-yl]amino}cyclopentyl)-2-- (2H-1,2,3-triazol-2-yl)benzamide; N-(4,4-Difluoro-2-{[5-(trifluoromethyl)pyrimidin-2-yl]amino}cyclopentyl)-- 2-(2H-1,2,3-triazol-2-yl)benzamide; N-(4,4-Difluoro-2-{[5-(trifluoromethyl)pyridin-2-yl]amino}cyclopentyl)-2-- (2H-1,2,3-triazol-2-yl)benzamide; N-[(1S,2S)-4,4-Difluoro-2-{[5-(trifluoromethoxy)pyridin-2-yl]amino}cyclop- entyl]-2-(2H-1,2,3-triazol-2-yl)benzamide; N-[(1S,2S)-4,4-Difluoro-2-{[3-fluoro-5-(trifluoromethyl)pyridin-2-yl]amin- o}cyclopentyl]-2-(2H-1,2,3-triazol-2-yl)benzamide; 2-(5-Ethoxypyrimidin-2-yl)-N-[(1S,2S)-2-{[5-trifluoromethyl)pyrazin-2-yl]- amino}cyclopentyl]benzamide; 2-Fluoro-6-methoxy-N-[(1S,2S)-2-{[5-(trifluoromethyl)pyrazin-2-yl]amino}c- yclopentyl]benzamide; N-[(1S,2S)-2-{[3-Methyl-5-(trifluoromethyl)pyridin-2-yl]amino}cyclopentyl- ]-3-(pyrimidin-2-yl)pyridine-2-carboxamide; N-[(1S,2S)-2-{[3-Fluoro-5-(trifluoromethyl)pyridin-2-yl]amino}cyclopentyl- ]-2-(pyrimidin-2-yl)benzamide; 5-Fluoro-N-[(1S,2S)-2-{[3-fluoro-5-(trifluoromethyl)pyridin-2-yl]amino}cy- clopentyl]-2-(pyrimidin-2-yl)benzamide; N-[(1S,2S)-2-{[3-Fluoro-5-(trifluoromethyl)pyridin-2-yl]amino}cyclopentyl- ]-2-(3-methyl-1,2,4-oxadiazol-5-yl)benzamide; 2-(3-Methyl-1,2,4-oxadiazol-5-yl)-N-[(1S,2S)-2-{[3-methyl-5-(trifluoromet- hyl)pyrazin-2-yl]amino}cyclopentyl]benzamide; N-[(1S,2S)-2-{[3-Cyclopropyl-5-(trifluoromethyl)pyrazin-2-yl]amino}cyclop- entyl]-3-(2H-1,2,3-triazol-2-yl)pyridine-2-carboxamide; N-[(1S,2S)-2-{[3-Cyclopropyl-5-(trifluoromethyl)pyrazin-2-yl]amino}cyclop- entyl]-3-(pyrimidin-2-yl)pyridine-2-carboxamide; N-[(1S,2S)-2-Methyl-2-{[5-(trifluoromethyl)pyrazin-2-yl]amino}cyclopentyl- ]-3-(pyrimidin-2-yl)pyridine-2-carboxamide; 2-(3-Methyl-1,2,4-oxadiazol-5-yl)-N-[(1S,2S)-2-methyl-2-{[5-(trifluoromet- hyl)pyrazin-2-yl]amino}cyclopentyl]benzamide; N-(2-{[3-Fluoro-5-(trifluoromethyl)pyridin-2-yl]amino}-2-methylcyclopenty- l)-3-(pyrimidin-2-yl)pyridine-2-carboxamide; N-[(1S,2S)-2-{[3-Fluoro-5-(trifluoromethyl)pyridin-2-yl]amino}cyclopentyl- ]-3-(pyrimidin-2-yl)pyridine-2-carboxamide; N-[(1S,2S)-2-{[3-Chloro-5-(trifluoromethyl)pyridin-2-yl]amino}cyclopentyl- ]-3-(pyrimidin-2-yl)pyridine-2-carboxamide; N-[(1S,2S)-2-{[3-Ethyl-5-(trifluoromethyl)pyrazin-2-yl]amino}cyclopentyl]- -2-(3-methyl-1,2,4-oxadiazol-5-yl)benzamide; N-[(1S,2S)-2-{[3-Ethyl-5-(trifluoromethyl)pyrazin-2-yl]amino}cyclopentyl]- -3-(pyrimidin-2-yl)pyridine-2-carboxamide; N-[(1S,2S)-2-{[3-Ethyl-5-(trifluoromethyl)pyrazin-2-yl]amino}cyclopentyl]- -2-(pyrimidin-2-yl)benzamide; N-(2-Methyl-2-{[5-(trifluoromethyl)pyrimidin-2-yl]amino}cyclopentyl)-3-(p- yrimidin-2-yl)pyridine-2-carboxamide; N-(2-Methyl-2-{[5-(trifluoromethyl)pyrimidin-2-yl]amino}cyclopentyl)-3-(2- H-1,2,3-triazol-2-yl)pyridine-2-carboxamide; N-(2-Methyl-2-{[5-(trifluoromethyl)pyridin-2-yl]amino}cyclopentyl)-3-(2H-- 1,2,3-triazol-2-yl)pyridine-2-carboxamide; N-(2-Methyl-2-{[5-(trifluoromethyl)pyridin-2-yl]amino}cyclopentyl)-3-(pyr- imidin-2-yl)pyridine-2-carboxamide; N-[(1S,2S)-2-{[5-(Difluoromethoxy)pyridin-2-yl]amino}-4,4-difluorocyclope- ntyl]-2-(2H-1,2,3-triazol-2-yl)benzamide; N-[(1S,2S)-2-{[3-Ethyl-5-(trifluoromethyl)pyrazin-2-yl]amino}cyclopentyl]- -5-fluoro-2-(pyrimidin-2-yl)benzamide; N-[(1S,2S)-2-{[3-Methyl-5-(trifluoromethyl)pyrazin-2-yl]amino}cyclopentyl- ]-3-(pyrimidin-2-yl)pyridine-2-carboxamide; 2-(5-Methyl-1,3,4-oxadiazol-2-yl)-N-[(1S,2S)-2-methyl-2-{[5-(trifluoromet- hyl)pyrazin-2-yl]amino}cyclopentyl]benzamide; enantiomers thereof and pharmaceutically acceptable salts of any of the foregoing. 12. The method of claim 1, further comprising administering to the subject a pharmaceutically acceptable adjuvant, diluent or carrier. 13. The method of claim 1, further comprising administering to the subject at least one therapeutic agent selected from the group consisting of: (i) an antidepressant selected from amitriptyline, amoxapine, bupropion, citalopram, clomipramine, desipramine, doxepin duloxetine, elzasonan, escitalopram, fluvoxamine, fluoxetine, gepirone, imipramine, ipsapirone, maprotiline, nortriptyline, nefazodone, paroxetine, phenelzine, protriptyline, reboxetine, robaizotan, sertraline, sibutramine, tianeptine, thionisoxetine, tranylcypromaine, trazodone, trimipramine, venlafaxine, vortioxetine, or an equivalent, a pharmaceutically active isomer, and a metabolite thereof; (ii) an antipsychotic selected from amisulpride, aripiprazole, asenapine, benzisoxidil, bifeprunox, brexpiprazole, carbamazepine, cariprazine, clozapine, chlorpromazine, debenzapine, divalproex, duloxetine, eszopiclone, haloperidol, iloperidone, lamotrigine, loxapine, lurasidone, mesoridazine, olanzapine, paliperidone, perlapine, perphenazine, phenothiazine, phenylbutlypiperidine, pimnozide, prochlorperazine, quetiapine, risperidone, sertindole, sulpiride, suproclone, suriclone, thioridazine, trifluoperazine, trimetozine, valproate, valproic acid, zopiclone, zotepine, zicronapine, ziprasidone, or equivalents, pharmaceutically active isomer(s), and metabolite(s) thereof; (iii) an anxiolytic selected from alnespirone, azapirones, benzodiazepines, barbiturates, adinazolam, alprazolam, balezepam, bentazepam, bromazepam, brotizolam, buspirone, clonazepam, clorazepate, chlordiazepoxide, cyprazepam, diazepam, diphenhydramine, estazolam, fenobam, flunitrazepam, flurazepam, fosazepam, lorazepam, lormetazepam, meprobamate, midazolam, nitrazepam, oxazepam, prazepam, quazepam, reclazepam, tracazolate, trepipam, temazepam, triazolam, uldazepam, zolazepam, or an equivalent, a pharmaceutically active isomer, and a metabolite thereof; (iv) an anticonvulsant selected from carbamazepine, valproate, lamotrigine, levetiracetam, gabapentin, or an equivalent, a pharmaceutically active isomer, and a metabolite thereof; (v) an Alzheimer's disease therapy selected from donepezil, galantamine, memantine, rivastigmine, tacrine, or an equivalent, a pharmaceutically active isomer, and a metabolite thereof; (vi) a Parkinson's disease therapy selected from L-dopa, ropinirole, pramipexole, monoamine oxidase type B (MAO-B) inhibitors such as deprenyl, selegiline and rasagiline, catechol-0-methyl transferase (COMT) inhibitors, adenosine A-2 inhibitors, dopamine re-uptake inhibitors, NMDA antagonists, nicotine agonists, and dopamine agonists, inhibitors of neuronal nitric oxide synthase, or an equivalent, a pharmaceutically active isomer, and a metabolite thereof; (vii) a migraine therapy selected from almotriptan, amantadine, botulinum toxin A, bromocriptine, butalbital, cabergoline, dichloralphenazone, dihydroergotamine, eletriptan, frovatriptan, lisuride, naratriptan, pergolide, pramipexole, rizatriptan, ropinirole, sumatriptan, topiramate, zolmitriptan, zomitriptan, or an equivalent, a pharmaceutically active isomer, and a metabolite thereof; (viii) a stroke therapy selected from abciximab, activase, citicoline, desmoteplase, or an equivalent, a pharmaceutically active isomer, and a metabolite thereof; (ix) a urinary incontinence therapy selected from darafenacin, duloxetine, falvoxate, mirabegron, oxybutynin, propiverine, robalzotan, solifenacin, tolterodine, or an equivalent, a pharmaceutically active isomer, and a metabolite thereof; (x) a neuropathic pain therapy selected from capsaicin, gabapentin, lidoderm, and pregabalin, or an equivalent, a pharmaceutically active isomer, and a metabolite thereof. 14. The method according to claim 13, wherein more than one therapeutic agent is administered. 15. The method of claim 1, wherein the subject is a mammal. 16. The method of claim 15, wherein the mammal is selected from the group consisting of: a mouse, a human, and a non-human primate. 17. The method of claim 1, wherein the administering step occurs orally, parenterally, by inhalation spray, rectally, nasally, buccally, vaginally, or via an implanted reservoir. 18. The method of claim 1, wherein the compound is formulated as a pharmaceutical composition in form of one of the group consisting of: a capsule, a tablet, a powder, a granule, an aqueous suspension, and a solution. 19. The method of claim 11, wherein the compound is N-[(1S,2S)-2-{[3-Ethyl-5-(trifluoromethyl)pyrazin-2-yl]amino}cyclopentyl]- -3-(2H-1,2,3-triazol-2-yl)pyridine-2-carboxamide.

Details for Patent 10,689,373

Applicant	Tradename	Biologic Ingredient	Dosage Form	BLA	Approval Date	Patent No.	Expiredate
Genentech, Inc.	ACTIVASE	alteplase	For Injection	103172	November 13, 1987		2038-06-01
Genentech, Inc.	CATHFLO ACTIVASE	alteplase	For Injection	103172	September 04, 2001		2038-06-01
Janssen Biotech, Inc.	REOPRO	abciximab	Injection	103575	December 22, 1994		2038-06-01